Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 32658841!ä!32658841 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Medicina+(B+Aires) 2020 ; 80 Suppl 3 (ä): 1-6 Nephropedia Template TP {{tp|p=32658841|t=2020. Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina |pdf=|usr=}}{{32658841}} gab.com Text Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina JO: Medicina (B Aires) http://www.kidney.de/pget.php?&tw=1&pmid=32658841 #FOAvip The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified EpAbs containing highly purified F(ab')2 fragments demonstrated to be safe and well tolerated. EpAbs are easy to manufacture allowing a fast development and scaling up for a treatment. Based on these ideas, we present a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein. Our product shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma. This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina. Twit Text FOAVip Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina ????Medicina (B Aires) http://www.kidney.de/pget.php?&tw=1&pmid=32658841 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32658841 #FOAvip English Wikipedia <ref>{{Cite pmid|32658841}}</ref> Desarrollo de un suero equino hiperinmune para el tratamiento de COVID-19 en Argentina #MMPMID32658841 Zylberman V; Sanguineti S; Pontoriero AV; Higa SV; Cerutti ML; Morrone Seijo SM; Pardo R; Munoz L; Acuna Intrieri ME; Alzogaray VA; Avaro MM; Benedetti E; Berguer PM; Bocanera L; Bukata L; Bustelo MS; Campos AM; Colonna M; Correa E; Cragnaz L; Dattero ME; Dellafiore M; Foscaldi S; Gonzalez JV; Guerra LL; Klinke S; Labanda MS; Lauche C; Lopez JC; Martinez AM; Otero LH; Peyric EH; Ponziani PF; Ramondino R; Rinaldi J; Rodriguez S; Russo JE; Russo ML; Saavedra SL; Seigelchifer M; Sosa S; Vilarino C; Lopez Biscayart P; Corley E; Spatz L; Baumeister EG; Goldbaum FA Medicina (B Aires) 2020[]; 80 Suppl 3 (ä): 1-6 PMID32658841show ga The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified EpAbs containing highly purified F(ab')2 fragments demonstrated to be safe and well tolerated. EpAbs are easy to manufacture allowing a fast development and scaling up for a treatment. Based on these ideas, we present a new therapeutic product obtained after immunization of horses with the receptor-binding domain of the viral Spike glycoprotein. Our product shows around 50 times more potency in in vitro seroneutralization assays than the average of convalescent plasma. This result may allow us to test the safety and efficacy of this product in a phase 2/3 clinical trial to be conducted in July 2020 in the metropolitan area of Buenos Aires, Argentina. |*Antibodies, Viral/chemistry/immunology/isolation & purification[MESH] |*Pandemics[MESH] |*Pneumonia, Viral[MESH] |*Spike Glycoprotein, Coronavirus[MESH] |Animals[MESH] |Argentina[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/*therapy[MESH] |Horses[MESH] |Humans[MESH] |Immune Sera/*immunology[MESH] |Immunization, Passive[MESH] |Immunoglobulin Fab Fragments/chemistry/*isolation & purification[MESH] |Immunoglobulin G/chemistry/*isolation & purification[MESH] |Neutralization Tests[MESH]Desarrollo de un suero equino hiperinmune para el tratamiento de COVID(epmc).pdf DeepDyve Pubget Overpricing